| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Department of Pediatrics, Wake Forest University School of Medicine, Winston-Salem, North Carolina; and 2Department of Medicine, Division of Infectious Diseases, University of Maryland, Baltimore, Maryland
Submitted 1 March 2005 ; accepted in final form 31 July 2005
Macrolide antibiotics decrease proinflammatory cytokine production in airway cells from subjects with chronic airway inflammation. However, in subjects with chronic obstructive pulmonary disease, short-term azithromycin (AZM) therapy causes a transient early increase in the blood neutrophil oxidative burst followed by a decrease in inflammatory markers with longer administration. We studied the effects of clarithromycin (CAM) and AZM on proinflammatory cytokine production from normal human bronchial epithelial (NHBE) cells. CAM decreased IL-8 over the first 6 h and then significantly increased interleukin (IL)-8 at 12–72 h after exposure (P < 0.0001). AZM also increased IL-8 at 24 and 48 h, and CAM increased granulocyte-macrophage colony-stimulating factor at 48 h. In the presence of LPS, both CAM and AZM dose-dependently increased IL-8 secretion over 24 h, but after 5 days of exposure to 10 µg/ml CAM there is suppression of IL-8 (P < 0.001). PD-98059, an inhibitor of MAP kinase/ERK kinase, inhibited CAM-induced IL-8 (P < 0.0001) and GM-CSF (P < 0.01) release. The p38 MAP kinase inhibitor SB-203580 increased CAM-induced IL-8 release (P < 0.001), and the c-jun NH2-terminal kinase inhibitor SP-600125 had no effect on IL-8. At 120 min and 6 h, CAM increased phospho-ERK1/2 (pERK) but not phospho-p38 or phospho-JNK. Over the first 90 min, CAM at 10 µg/ml inhibited pERK and then increased pERK in parallel with measured IL-8 secretion. After daily CAM exposure for 5 days, both IL-8 and pERK returned to baseline. The p38 MAP kinase inhibitor, SB-203580 increased ERK phosphorylation and IL-8 secretion. These results suggest that macrolide antibiotics can differentially modulate proinflammatory cytokine secretion in NHBE cells, in part through ERK.
macrolides; interleukin-8; extracellular signal-regulated mitogen-activated protein kinases; clarithromycin; anti-inflammatory agents and inflammation mediators
This article has been cited by other articles:
|
|
 |
|
  H. C. Steel, A. J. Theron, G. R. Tintinger, and R. Anderson Posaconazole attenuates leukotriene B4 release and uptake of calcium by chemoattractant-activated human neutrophils: a potential strategy to control neutrophil-mediated inflammation J. Antimicrob. Chemother., November 1, 2009; 64(5): 1008 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bosnar, B. Bosnjak, S. Cuzic, B. Hrvacic, N. Marjanovic, I. Glojnaric, O. Culic, M. J. Parnham, and V. E. Haber Azithromycin and Clarithromycin Inhibit Lipopolysaccharide-Induced Murine Pulmonary Neutrophilia Mainly through Effects on Macrophage-Derived Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-1{beta} J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 104 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F Idris, E. R Chilvers, C. Haworth, D. McKeon, and A. M Condliffe Azithromycin therapy for neutrophilic airways disease: myth or magic? Thorax, March 1, 2009; 64(3): 186 - 189. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nakanishi, D. Kobayashi, Y. Asano, T. Sakurai, M. Kashimura, S. Okuyama, Y. Yoneda, S. D. Shapiro, and K. Takayama Clarithromycin Prevents Smoke-induced Emphysema in Mice Am. J. Respir. Crit. Care Med., February 15, 2009; 179(4): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Starner, J. D. Shrout, M. R. Parsek, P. C. Appelbaum, and G. Kim Subinhibitory Concentrations of Azithromycin Decrease Nontypeable Haemophilus influenzae Biofilm Formation and Diminish Established Biofilms Antimicrob. Agents Chemother., January 1, 2008; 52(1): 137 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shinkai, Y. S. Lopez-Boado, and B. K. Rubin Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin J. Antimicrob. Chemother., June 1, 2007; 59(6): 1096 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Blau, K. Klein, I. Shalit, D. Halperin, and I. Fabian Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-{kappa}B activation in a cystic fibrosis epithelial cell line Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L343 - L352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shinkai, J. Tamaoki, H. Kobayashi, S. Kanoh, K. Motoyoshi, T. Kute, and B. K. Rubin Clarithromycin Delays Progression of Bronchial Epithelial Cells from G1 Phase to S Phase and Delays Cell Growth via Extracellular Signal-Regulated Protein Kinase Suppression. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1738 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Slevogt, B. Schmeck, C. Jonatat, J. Zahlten, W. Beermann, V. van Laak, B. Opitz, S. Dietel, P. D. N'Guessan, S. Hippenstiel, et al. Moraxella catarrhalis induces inflammatory response of bronchial epithelial cells via MAPK and NF-{kappa}B activation and histone deacetylase activity reduction Am J Physiol Lung Cell Mol Physiol, May 1, 2006; 290(5): L818 - L826. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
